Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance

37
5
Favorite

Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance

Seeking Alpha2022-02-04

Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.
Revenue of €9.99B misses by €120M(+6.5% Y/Y).
Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.
Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.
General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestitures
CHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.
2022 financial outlook: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（5）

evauoz
·2022-02-04
Buy?
Reply
1
Report
Fold Replies
- evauoz:
  buy?
  2022-02-04
  Reply
  Report
Kitsonlin
·2022-02-04
Evening
Reply
Like
Report
KYBoo
·2022-02-04
Good
Reply
3
Report
Fold Replies
- yourself:
  hi there I am not r moving to do the interview process is working on it in the UK and the carpets
  2022-02-04
  Reply
  Report
- KYBoo:
  gpof
  2022-02-04
  Reply
  Report
SiewMailing
·2022-02-04
Like
Reply
2
Report
Fold Replies
- Dollarvan:
  Okay
  2022-02-05
  Reply
  Report
- LenLee:
  Ok
  2022-02-04
  Reply
  Report
rickson
·2022-02-04
a
Reply
7
Report
Fold Replies
- Kitsonlin:
  up
  2022-02-04
  Reply
  Report

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1162337054?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2022-02-04 16:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162337054","market":"us","top_or_hot":-1,"title":"Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance","media":"Seeking Alpha","content":"<html><head></head><body><ul><li>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.</li><li>Revenue of €9.99B misses by €120M(+6.5% Y/Y).</li><li>Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.</li><li>Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.</li><li>General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestitures</li><li>CHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.</li><li><b>2022 financial outlook</b>: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-04 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +...</p>\n\n<a href=\"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance","article_id":"1162337054","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162337054","pubTimestamp":1643964793,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特"},"translate_title":"赛诺菲非公认会计原则每股收益1.38欧元超过预期0.02欧元，收入999.9亿欧元低于预期1.2亿欧元；启动22财年指南","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9},"content_text":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestituresCHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.2022 financial outlook: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9098084275,"gmtCreate":1643972408380,"gmtModify":1676533877539,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4087513826666000","idStr":"4087513826666000"},"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9098084275","repostId":1162337054,"repostType":4,"repost":{"id":"1162337054","kind":"news","pubTimestamp":1643964793,"share":"https://ttm.financial/m/news/1162337054?lang=&edition=full_marsco","pubTime":"2022-02-04 16:53","market":"us","language":"en","title":"Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1162337054","media":"Seeking Alpha","summary":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by","content":"<html><head></head><body><ul><li>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.</li><li>Revenue of €9.99B misses by €120M(+6.5% Y/Y).</li><li>Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.</li><li>Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.</li><li>General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestitures</li><li>CHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.</li><li><b>2022 financial outlook</b>: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-04 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +...</p>\n\n<a href=\"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162337054","content_text":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestituresCHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.2022 financial outlook: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100422009,"gmtCreate":1643972415049,"gmtModify":1663243273775,"authorId":4087513826666000,"author":{"id":4087513826666000,"idStr":"4087513826666000","authorId":4087513826666000,"name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9098084275,"type":1,"supId":0,"prevId":0,"content":"buy?","text":"buy?","html":"buy?"}],"langContent":"EN"},{"id":9098010649,"gmtCreate":1643966452828,"gmtModify":1676533876873,"author":{"id":"4088412711170620","authorId":"4088412711170620","name":"Kitsonlin","avatar":"https://community-static.tradeup.com/news/8f861facf7d7b6166cb50fa387771267","vip":1,"hat":"https://static.tigerbbs.com/1c1eed764d9c7ff83dc093fbb9a96bc2","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4088412711170620","idStr":"4088412711170620"},"htmlText":"Evening","listText":"Evening","text":"Evening","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098010649","repostId":1162337054,"repostType":4,"repost":{"id":"1162337054","kind":"news","pubTimestamp":1643964793,"share":"https://ttm.financial/m/news/1162337054?lang=&edition=full_marsco","pubTime":"2022-02-04 16:53","market":"us","language":"en","title":"Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1162337054","media":"Seeking Alpha","summary":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by","content":"<html><head></head><body><ul><li>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.</li><li>Revenue of €9.99B misses by €120M(+6.5% Y/Y).</li><li>Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.</li><li>Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.</li><li>General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestitures</li><li>CHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.</li><li><b>2022 financial outlook</b>: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-04 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +...</p>\n\n<a href=\"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162337054","content_text":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestituresCHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.2022 financial outlook: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098037447,"gmtCreate":1643966286339,"gmtModify":1676533876856,"author":{"id":"3581501341719005","authorId":"3581501341719005","name":"KYBoo","avatar":"https://static.tigerbbs.com/43072e3bdf1be8a6c0fb9e0d7c8a0558","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3581501341719005","idStr":"3581501341719005"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9098037447","repostId":1162337054,"repostType":4,"repost":{"id":"1162337054","kind":"news","pubTimestamp":1643964793,"share":"https://ttm.financial/m/news/1162337054?lang=&edition=full_marsco","pubTime":"2022-02-04 16:53","market":"us","language":"en","title":"Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1162337054","media":"Seeking Alpha","summary":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by","content":"<html><head></head><body><ul><li>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.</li><li>Revenue of €9.99B misses by €120M(+6.5% Y/Y).</li><li>Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.</li><li>Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.</li><li>General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestitures</li><li>CHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.</li><li><b>2022 financial outlook</b>: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-04 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +...</p>\n\n<a href=\"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162337054","content_text":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestituresCHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.2022 financial outlook: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100421959,"gmtCreate":1643971769633,"gmtModify":1663243271243,"authorId":4089375229568220,"author":{"id":4089375229568220,"idStr":"4089375229568220","authorId":4089375229568220,"name":"yourself","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9098037447,"type":1,"supId":100421440,"prevId":0,"content":"hi there I am not r moving to do the interview process is working on it in the UK and the carpets","text":"hi there I am not r moving to do the interview process is working on it in the UK and the carpets","html":"hi there I am not r moving to do the interview process is working on it in the UK and the carpets"},{"id":100421440,"gmtCreate":1643966298485,"gmtModify":1663243270733,"authorId":3581501341719005,"author":{"id":3581501341719005,"idStr":"3581501341719005","authorId":3581501341719005,"name":"KYBoo","avatar":"https://static.tigerbbs.com/43072e3bdf1be8a6c0fb9e0d7c8a0558","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9098037447,"type":1,"supId":0,"prevId":0,"content":"gpof","text":"gpof","html":"gpof"}],"langContent":"EN"},{"id":9098036309,"gmtCreate":1643965070513,"gmtModify":1676533876736,"author":{"id":"4098273802374380","authorId":"4098273802374380","name":"SiewMailing","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4098273802374380","idStr":"4098273802374380"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9098036309","repostId":1162337054,"repostType":4,"repost":{"id":"1162337054","kind":"news","pubTimestamp":1643964793,"share":"https://ttm.financial/m/news/1162337054?lang=&edition=full_marsco","pubTime":"2022-02-04 16:53","market":"us","language":"en","title":"Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1162337054","media":"Seeking Alpha","summary":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by","content":"<html><head></head><body><ul><li>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.</li><li>Revenue of €9.99B misses by €120M(+6.5% Y/Y).</li><li>Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.</li><li>Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.</li><li>General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestitures</li><li>CHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.</li><li><b>2022 financial outlook</b>: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-04 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +...</p>\n\n<a href=\"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162337054","content_text":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestituresCHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.2022 financial outlook: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100430158,"gmtCreate":1644033775477,"gmtModify":1663243312345,"authorId":3555014251535651,"author":{"id":3555014251535651,"idStr":"3555014251535651","authorId":3555014251535651,"name":"Dollarvan","avatar":"https://static.tigerbbs.com/0316ab12b442ee2cd79936de06de5089","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.79%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9098036309,"type":1,"supId":0,"prevId":0,"content":"Okay","text":"Okay","html":"Okay"},{"id":100421375,"gmtCreate":1643965420712,"gmtModify":1663243270541,"authorId":3579600451849224,"author":{"id":3579600451849224,"idStr":"3579600451849224","authorId":3579600451849224,"name":"LenLee","avatar":"https://community-static.tradeup.com/news/0a33f683a9a90d13042ad6380b6c1d05","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9098036309,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":9098036986,"gmtCreate":1643965069659,"gmtModify":1676533876728,"author":{"id":"4087654114933110","authorId":"4087654114933110","name":"rickson","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","vip":1,"crmLevel":1,"crmLevelSwitch":1,"authorIdStr":"4087654114933110","idStr":"4087654114933110"},"htmlText":"a","listText":"a","text":"a","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9098036986","repostId":1162337054,"repostType":4,"repost":{"id":"1162337054","kind":"news","pubTimestamp":1643964793,"share":"https://ttm.financial/m/news/1162337054?lang=&edition=full_marsco","pubTime":"2022-02-04 16:53","market":"us","language":"en","title":"Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1162337054","media":"Seeking Alpha","summary":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by","content":"<html><head></head><body><ul><li>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.</li><li>Revenue of €9.99B misses by €120M(+6.5% Y/Y).</li><li>Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.</li><li>Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.</li><li>General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestitures</li><li>CHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.</li><li><b>2022 financial outlook</b>: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-04 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +...</p>\n\n<a href=\"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162337054","content_text":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestituresCHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.2022 financial outlook: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100421450,"gmtCreate":1643966461081,"gmtModify":1663243271143,"authorId":4088412711170620,"author":{"id":4088412711170620,"idStr":"4088412711170620","authorId":4088412711170620,"name":"Kitsonlin","avatar":"https://community-static.tradeup.com/news/8f861facf7d7b6166cb50fa387771267","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9098036986,"type":1,"supId":0,"prevId":0,"content":"up","text":"up","html":"up"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":37,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}